[Gorodenkoff/Adobe Stock]
Modern pharma: Evolving through specialized strategiesThe pharmaceutical trend toward increasing concentration appears to be gaining momentum. On September 15, Novartis shareholders approved the company’s proposed spinoff of Sandoz, the generics and biosimilars unit. The company anticipates the deal to close in early October. Similarly, Sanofi is also taking a scalpel to its operations, offloading a selection of its central nervous system medications to Pharmanovia.
Sanofi, similar to several other of its pharma peers, is aiming to realign its portfolio, emphasizing areas where it can drive innovation and deliver robust growth.
Last week, Johnson & Johnson, for instance, announced a rebrand that traded its historic ‘Janssen’ pharma moniker for ‘Johnson & Johnson Innovative Medicine.’ The move is part of a broader initiative to priorit…